The price of Pfizer Inc. (NYSE:PFE) shares last traded on Wall Street rose 0.58% to $48.33.
Based on available information, 22 analysts follow Pfizer Inc. (NYSE:PFE). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $75.00 and a low of $44.00, we find $52.30. Given the previous closing price of $48.05, this indicates a potential upside of 8.84 percent. PFE stock price is now 6.63% away from the 50-day moving average and -1.77% away from the 200-day moving average. The market capitalization of the company currently stands at $269.99B.
Among analysts, 12 rate the stock a hold while 10 rate it a buy. Brokers who have rated the stock have averaged $54.31 as their price target over the next twelve months.
With the price target of $55, SVB Leerink recently initiated with Mkt Perform rating for Pfizer Inc. (NYSE: PFE)., while ‘BofA Securities’ rates the stock as ‘Buy’.
In other news, DAMICO JENNIFER B., SVP & Controller sold 4,218 shares of the company’s stock on Jun 07. The stock was sold for $227,603 at an average price of $53.96. Upon completion of the transaction, the SVP & Controller now directly owns 10,846 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, SVP & Controller DAMICO JENNIFER B. sold 4,000 shares of the business’s stock. A total of $202,000 was realized by selling the stock at an average price of $50.50. This leaves the insider owning 15,064 shares of the company worth $0.73 million. Insiders disposed of 991,613 shares of company stock worth roughly $47.92 million over the past 1 year. A total of 0.05% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PFE stock. A new stake in Pfizer Inc. shares was purchased by TWO SIGMA INVESTMENTS, LP during the first quarter worth $134,342,000. AUSTRALIANSUPER PTY LTD invested $111,133,000 in shares of PFE during the first quarter. In the first quarter, RENAISSANCE TECHNOLOGIES LLC acquired a new stake in Pfizer Inc. valued at approximately $96,179,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in PFE for approximately $71,648,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC purchased a new stake in PFE valued at around $51,226,000 in the second quarter. In total, there are 3,899 active investors with 70.40% ownership of the company’s stock.
A candlestick chart of Pfizer Inc. (NYSE: PFE) showed a price of $47.80 on Thursday morning. During the past 12 months, Pfizer Inc. has had a low of $41.44 and a high of $61.71. As of last week, the company has a debt-to-equity ratio of 0.40, a current ratio of 1.60, and a quick ratio of 1.40. The fifty day moving average price for PFE is $45.32 and a two-hundred day moving average price translates $49.20 for the stock.
The latest earnings results from Pfizer Inc. (NYSE: PFE) was released for Jul, 2022. According to the Drug Manufacturers – General Company, earnings per share came in at $22.13, beating analysts’ expectations of $19.53 by 2.6. This compares to $0.00 EPS in the same period last year. The net profit margin was 29.90% and return on equity was 35.10% for PFE. The company reported revenue of $22.64 billion for the quarter, compared to $24.04 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.81 percent. For the current quarter, analysts expect PFE to generate $229.15B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/05/2022. Investors who held shares on 11/04/2022 were paid a $0.40 dividend. On an annualized basis, this represents a $1.60 dividend and a 3.31% percent yield. There was an ex-dividend date of 11/03/2022 for this dividend. In terms of dividend payout ratio, PFE is presently at 29.90%.
Pfizer Inc.(PFE) Company Profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.